If you would like to download a copy of the agenda, please click here.

Monday, April 4, 2022

08:30 am - 08:45 am EST
Welcome & Opening Remarks

Jeremy Davis, M.D., Center for Cancer Research, NCI
Bill Dahut, M.D., Center for Cancer Research, NCI


Session 1

Chair:  Jeremy Davis, M.D., Center for Cancer Research, NCI

08:45 am - 09:15 am EST
Epidemiologic Trends in Diffuse-type Gastric Cancer

Constanza Camargo, Ph.D., Division of Cancer Epidemiology and Genetics, NCI

09:15 am - 09:45 am EST
Inherited Gastric Cancer Syndromes

Sonia Kupfer, M.D., University of Chicago

09:45 am - 10:15 am EST
2020 Wanaka Hereditary Diffuse Gastric Cancer Guidelines

Parry Guilford, Ph.D., University of Otago

10:15 am - 10:45 am EST

Session 2

Chair:  Carla Oliveira, Ph.D., Ipatimup

10:45 am - 11:15 am EST
Morphologic and Transcriptomic Diversity of Early Diffuse Gastric Cancer

Fatima Carneiro, M.D., Ipatimup Diagnostics

11:15 am - 11:45 am EST
Importance of RHOA Mutations in Diffuse Gastric Cancer

Adam Bass, M.D., Dana-Farber Cancer Institute

11:45 am - 12:15 pm EST
CTNNA1 and Other Genes Implicated in HDGC

Patrick Benusiglio, M.D., Ph.D., Sorbonne Université

12:15 pm - 01:30 pm EST

Session 3

Chair:  David Huntsman, M.D., University of British Columbia

01:30 pm - 02:00 pm EST
Safety of Endoscopic Gastric Cancer Surveillance

Bilal Asif, M.D., National Institute of Diabetes and Digestive and Kidney Diseases, NIH

02:00 pm - 02:30 pm EST
Long-term Sequelae of Prophylactic Total Gastrectomy for CDH1

Jeremy Davis, M.D., Center for Cancer Research, NCI

02:30 pm - 03:00 pm EST
Regional Therapies for Diffuse-type Carcinomatosis

Brian Badgwell, M.D., MD Anderson Cancer Center

03:00 pm - 03:15 pm EST

Session 4

Chair:  Michael Yaffe, M.D., Ph.D., Center for Cancer Research, NCI

03:15 pm - 03:45 pm EST
Adoptive Cell Therapy for Personalized Treatment of Gastric Cancer

Scott Norberg, M.D., Center for Cancer Research, NCI

03:45 pm - 04:15 pm EST
Toward a Chemoprevention Strategy in HDGC

Parry Guilford, Ph.D., University of Otago

04:15 pm EST

Tuesday, April 5, 2022

Session 5
Chair:  Marc Tischkowitz, M.D., Ph.D., Cambridge University

09:00 am - 09:30 am EST
CDH1 Penetrance Estimates and their Impact on Clinical Cancer Risk Assessment

James Ford, M.D., Stanford University

09:30 am - 10:00 am EST
Multi-Gene Panels and Cascade Genetic Testing

Grace-Ann Fasaye, ScM, CGC, Center for Cancer Research, NCI

10:00 am - 10:30 am EST
RNA Genetic Testing for Hereditary Cancer

Rachid Karam, Ph.D., Ambry Genetics

10:30 am - 11:00 am EST

Session 6

Chair:  Tanya Bisseling, M.D., Radboudumc

11:00 am - 11:30 am EST
Life After Prophylactic Total Gastrectomy (LAP-TG) Study

Geoffrey Roberts, Ph.D., FRCS., Cambridge University

11:30 am - 12:00 pm EST
Macro- and Micronutrient Deficiencies Following Total Gastrectomy

Rachael Lopez, MPH, RD, CSO., Clinical Center, NIH

12:00 pm - 12:30 pm EST
A Patient’s View: Life with HDGC

Johanna D’Addario, MHS, PA-C., Yale New Haven Health

12:30 pm EST

Session 7
Chair:  Jeremy Davis, M.D., Center for Cancer Research, NCI

01:30 pm - 02:30 pm EST
Panel Discussion: What patients with CDH1 need us to hear

Panelists: Melanie Kirk, Amanda Endy, Jeff Ley, Randy Buckley and Franklin Adams

02:30 pm - 03:00 pm EST
Participation in Clinical Trials and Registries

Dylan Davison, No Stomach For Cancer, Inc.

03:00 pm - 03:30 pm EST
Call to Action and Closing Remarks

Jeremy Davis, M.D., Center for Cancer Research, NCI

03:30 pm - 03:35 pm EST